SurModics IVD Part of Breakthrough Smartphone-Driven HIV Test
March 18 2015 - 8:00AM
Business Wire
SurModics, Inc. (Nasdaq:SRDX) contributed a key component for a
diagnostic device that attaches to a smartphone and detects HIV
quickly, accurately and inexpensively.
“This device is a great example of the benefits of point-of-care
diagnostics, especially in developing countries,” said Joe Stich,
Vice President and General Manager of SurModics IVD, the company’s
in vitro diagnostic business. “We are proud to have been a small
part of what appears to be a promising new point-of-care
device.”
The new and yet unnamed device developed by Columbia University
has been tested in a small clinical trial in Kingali, Rwanda.
Results of the trial were published in February in Science
Translational Medicine.1
In preparing the diagnostic test’s cassettes, researchers at
Columbia University used SurModics’ StabilCoat® immunoassay
stabilizer during physisorption of disease-specific capture
proteins. Their paper noted that they found the protein retained
its function over three weeks at 60°C. The high-temperature
conditions were intended to mimic actual shipping and
transportation conditions in Rwanda. Advanced preparation of the
cassettes at Columbia helped ensure “plug-and-play” readiness upon
arrival in Africa.1
StabilCoat stabilizer is considered the gold standard for
stabilizing proteins in the dried state. It is also an excellent
blocking agent that can be dried down or used as a blocker for
same-day assays. In this trial, StabilCoat solution helped minimize
noise and non-specific binding while delivering high signal to
enable accurate detection of the three disease states in the test:
HIV, syphilis (treponemal) and syphilis (non-treponemal).1
In addition to product, SurModics senior scientists provided
guidance to members of the research team over several months to
help optimize reagent stability in loading, storing and shipping
the cassettes. “It’s exciting and rewarding to have been part of
this effort,” said Sr. Scientist Sean Lundquist. “SurModics
routinely partners with assay developers on innovative projects.
It’s always gratifying to help bring new point-of-care devices to
fruition.”
According to the researchers’ paper, the new device costs about
$34 to make and delivers results in 15 minutes. Results of the
study indicate that the new smartphone accessory appears to be as
accurate as conventional diagnostic tests, which are run on ELISA
equipment typically costing about $18,450.
About SurModics, Inc.SurModics partners with the world's
leading and emerging medical device, diagnostic and life sciences
companies to develop and commercialize innovative products designed
to improve lives by enabling the detection and treatment of
disease. The company’s core offerings include surface modification
coating technologies that impart lubricity, prohealing and
biocompatibility characteristics and components for in vitro
diagnostic test kits and microarrays. SurModics is headquartered in
Eden Prairie, Minnesota. For more information about the Company,
visit www.surmodics.com. The content of SurModics’ website is not
part of this press release or part of any filings that the Company
makes with the SEC.
1. T. Laksanasopin, T. W. Guo, S. Nayak, A. A. Sridhara, S. Xie,
O. O. Olowookere,P. Cadinu, F. Meng, N. H. Chee, J. Kim, C. D.
Chin, E. Munyazesa, P. Mugwaneza, A. J. Rai,V. Mugisha, A. R.
Castro, D. Steinmiller, V. Linder, J. E. Justman, S. Nsanzimana, S.
K. Sia, A smartphone dongle for diagnosis of infectious diseases at
the point of care. Sci Transl Med 7, 273re1 (2015).
SurModics, Inc.Joe Stich, 952-500-7000Vice President and
General ManagerIn Vitro Diagnosticsir@surmodics.com
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Sep 2023 to Sep 2024